Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $32

Benzinga Newsdesk www.benzinga.com Negative 57.8%

Neg 57.8% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $40 to $32.